QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Biotechnology

QED Therapeutics

Matt Outten

Ariana Salvatici

Joyce Velez

Vanessa Solis

Quoc M.

Mike Monteith

Deborah Mortensen

David van Veenhuyzen

Dave Martin

Daniela Rogoff, MD, PhD.

Rick Panicucci

Clinical Development

Clinical Operations Team

Leadership Team

Teams at QED Therapeutics

Clinical Development

Clinical Operations Team

Leadership Team